Cargando…

Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines

Detalles Bibliográficos
Autores principales:	Dillman, Robert O, McClay, Edward, Amatruda, Thomas, Semeniuk, George, Haskins, Clark, Weber, Robert, Burtzo, David, DePriest, Carol, Carbonell, Denysha, Cornforth, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649581/ http://dx.doi.org/10.1186/2051-1426-3-S2-P202

Ejemplares similares

Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
por: Dillman, Robert O., et al.
Publicado: (2018)

Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
por: Dillman, Robert O, et al.
Publicado: (2019)

Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment
por: Dillman, Robert O., et al.
Publicado: (2015)

High-dose IL-2 in metastatic melanoma: better survival in patients who also received patient-specific autologous tumor cell vaccine
por: Dillman, Robert O, et al.
Publicado: (2013)

Autologous Peripheral Blood Mononuclear Cell Recognition of Autologous Proliferating Tumor Cells in the Context of a Patient-Specific Vaccine Trial
por: Cornforth, A. N., et al.
Publicado: (2011)

Phase III randomized, double-blinded, placebo-controlled multicenter trial of melapuldencil-t: autologous dendritic cells loaded with irradiated autologous tumor cells (dc-tc) in gm-csf in patients with metastatic melanoma
por: Dillman, Robert, et al.
Publicado: (2014)

Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
por: Nistor, Gabriel I., et al.
Publicado: (2020)

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
por: Dillman, Robert O., et al.
Publicado: (2023)

Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines
por: Dillman, Robert O., et al.
Publicado: (2019)

Correlation between subsets of tumor-infiltrating immune cells and risk stratification in patients with cervical cancer
por: Chen, Rui, et al.
Publicado: (2019)

Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
por: Dillman, Robert O.
Publicado: (2016)

Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
por: de Gruijl, Tanja D., et al.
Publicado: (2008)

Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets
por: Duinkerken, Sanne, et al.
Publicado: (2019)

Transcriptional specialization of human dendritic cell subsets in response to microbial vaccines
por: Banchereau, Romain, et al.
Publicado: (2014)

Phenotypic and functional changes of T cell subsets after CoronaVac vaccination
por: Phoksawat, Wisitsak, et al.
Publicado: (2022)

Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment
por: Dillman, Robert Owen, et al.
Publicado: (2019)

The Quest for a Vaccine That Yields Tumor-Killing T cells
Publicado: (2004)

Dendritic-Tumor Fusion Cell-Based Cancer Vaccines
por: Koido, Shigeo
Publicado: (2016)

Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B positive patients with hepatocellular carcinoma
por: Bayer, Michael, et al.
Publicado: (2014)

Fusions between dendritic cells and whole tumor cells as anticancer vaccines
por: Koido, Shigeo, et al.
Publicado: (2013)

Impact of Vaccination on Distribution of T Cell Subsets in Antiretroviral-Treated HIV-Infected Children
por: Thitilertdecha, Premrutai, et al.
Publicado: (2017)

In vitro-activated tumor-bearing host T cells and the effectiveness of tumor vaccine immunotherapy
por: Li, Qi-ling, et al.
Publicado: (2012)

Effect of Multiple Vaccinations with Tumor Cell-Based Vaccine with Codon-Modified GM-CSF on Tumor Growth in a Mouse Model
por: Qiu, Jiantai Timothy, et al.
Publicado: (2019)

Vaccination against histomonosis limits pronounced changes of B cells and T-cell subsets in turkeys and chickens
por: Mitra, Taniya, et al.
Publicado: (2017)

Senescent cancer cell vaccines induce cytotoxic T cell responses targeting primary tumors and disseminated tumor cells
por: Liu, Yue, et al.
Publicado: (2023)

Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors
por: Aguilar, Robert, et al.
Publicado: (2017)

Dendritic Cells The Tumor Microenvironment and the Challenges for an Effective Antitumor Vaccination
por: Benencia, Fabian, et al.
Publicado: (2012)

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines
por: Goyvaerts, Cleo, et al.
Publicado: (2015)

Optimization of Whole Tumor Cell Vaccines by Interaction with Phagocytic Receptors
por: Korbelik, Mladen
Publicado: (2021)

Antitumor Cell-Complex Vaccines Employing Genetically Modified Tumor Cells and Fibroblasts
por: Miguel, Antonio, et al.
Publicado: (2014)

Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine
por: Dillman, Robert O., et al.
Publicado: (2019)

Allogeneic tumor cell line-based vaccines: A good alternative to autologous and cancer stem cell vaccines in colorectal cancer
por: Rafieenia, Fatemeh, et al.
Publicado: (2021)

Circulating Tfh cell and subsets distribution are associated with low‐responsiveness to hepatitis B vaccination
por: Yin, Mingjuan, et al.
Publicado: (2021)

NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans
por: Wagstaffe, Helen R., et al.
Publicado: (2022)

Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
por: Bota, Daniela A., et al.
Publicado: (2022)

A requirement for trypsin-sensitive cell-surface components for cell-cell interactions of embryonic neural retina cells
por: McClay, DR, et al.
Publicado: (1977)

Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site
por: Thoreau, Maxime, et al.
Publicado: (2015)

Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell
por: Diao, Lu, et al.
Publicado: (2023)

Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines
por: Koido, Shigeo, et al.
Publicado: (2011)

TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines
por: Jordan, Kimberly R., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rbckvqrsc7r0st59kfgps9a8ut